CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues
Revenues	$ 2,012	$ 2,016
Expenses
Selling, general and administrative	633	587
Research and development	122	117
Amortization of intangible assets	436	489
Asset impairments	14	3
Restructuring and integration costs	4	20
Acquisition-related contingent consideration	13	(21)
Other expense (income), net	23	(3)
Total expenses	1,764	1,729
Operating income	248	287
Interest income	7	4
Interest expense	(396)	(406)
Loss on extinguishment of debt	(24)	(7)
Foreign exchange and other	(13)	0
Loss before benefit from income taxes	(178)	(122)
Benefit from income taxes	26	74
Net loss	(152)	(48)
Net income attributable to noncontrolling interest	0	(4)
Net loss attributable to Bausch Health Companies Inc.	$ (152)	$ (52)
Basic and diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)	$ (0.43)	$ (0.15)
Basic and diluted weighted-average common shares (in shares)	353.4	351.3
Product sales
Revenues
Revenues	$ 1,986	$ 1,989
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	505	524
Other revenues
Revenues
Revenues	26	27
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	$ 14	$ 13